Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Vasoconstriction
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Examples=== Examples include [[stimulants]], [[amphetamine]]s, and [[antihistamine]]s. Many are used in medicine to treat [[hypotension]] and as [[topical decongestant]]s. Vasoconstrictors are also used clinically to increase [[blood pressure]] or to reduce local blood flow. [[Local anesthetics and vasoconstrictors|Vasoconstrictors mixed with local anesthetics]] are used to increase the duration of local anesthesia by constricting the blood vessels, thereby safely concentrating the anesthetic agent for an extended duration, as well as reducing [[hemorrhage]].<ref>{{cite journal |author=Yagiela JA |title=Vasoconstrictor agents for local anesthesia |journal=Anesth Prog |volume=42 |issue=3–4 |pages=116–20 |year=1995 |pmid=8934977 |pmc=2148913}}</ref><ref>{{cite journal |last1=Moodley |first1=D. S. |title=Local anaesthetics in dentistry - Part 3: Vasoconstrictors in local anaesthetics |journal=South African Dental Journal |date=May 2017 |volume=72 |issue=4 |pages=176–178 |hdl=10566/3893 |hdl-access=free }}</ref> The [[routes of administration]] vary. They may be both systemic and topical. For example, [[pseudoephedrine]] is taken orally and [[phenylephrine]] is topically applied to the nasal passages or eyes.<ref>{{cite journal |last1=Salerno |first1=Stephen M. |last2=Jackson |first2=Jeffrey L. |last3=Berbano |first3=Elizabeth P. |title=Effect of Oral Pseudoephedrine on Blood Pressure and Heart Rate: A Meta-analysis |journal=Archives of Internal Medicine |date=8 August 2005 |volume=165 |issue=15 |pages=1686–1694 |doi=10.1001/archinte.165.15.1686 |pmid=16087815 }}</ref><ref>{{cite journal |last1=Horak |first1=Friedrich |last2=Zieglmayer |first2=Petra |last3=Zieglmayer |first3=René |last4=Lemell |first4=Patrick |last5=Yao |first5=Ruji |last6=Staudinger |first6=Heribert |last7=Danzig |first7=Melvyn |title=A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber |journal=Annals of Allergy, Asthma & Immunology |date=February 2009 |volume=102 |issue=2 |pages=116–120 |doi=10.1016/s1081-1206(10)60240-2 |pmid=19230461 }}</ref> Examples include:<ref>{{cite book |doi=10.1007/7854_2016_64 |chapter=Pharmacology and Toxicology of N-Benzylphenethylamine ('NBOMe') Hallucinogens |title=Neuropharmacology of New Psychoactive Substances (NPS) |series=Current Topics in Behavioral Neurosciences |date=2017 |last1=Halberstadt |first1=Adam L. |volume=32 |pages=283–311 |pmid=28097528 |isbn=978-3-319-52442-9 }}</ref><ref>{{cite journal |last1=Echeverri |first1=Darío |last2=Montes |first2=Félix R. |last3=Cabrera |first3=Mariana |last4=Galán |first4=Angélica |last5=Prieto |first5=Angélica |title=Caffeine's Vascular Mechanisms of Action |journal=International Journal of Vascular Medicine |date=25 August 2010 |volume=2010 |pages=1–10 |doi=10.1155/2010/834060 |pmid=21188209 |pmc=3003984 |doi-access=free }}</ref><ref>{{Cite journal |last1=Laccourreye |first1=O. |last2=Werner |first2=A. |last3=Giroud |first3=J.-P. |last4=Couloigner |first4=V. |last5=Bonfils |first5=P. |last6=Bondon-Guitton |first6=E. |date=2015 |title=Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants |journal=European Annals of Otorhinolaryngology, Head and Neck Diseases |volume=132 |issue=1 |pages=31–34 |doi=10.1016/j.anorl.2014.11.001 |pmid=25532441 |doi-access=free }}</ref> {| class="wikitable" |- !Vasoconstrictors |- |[[25I-NBOMe]] |- |[[Amphetamine]]s |- |[[Alpha-Methyltryptamine|AMT]] |- |[[Antihistamines]] |- |[[Caffeine]] |- |[[Cocaine]] |- |[[2,5-Dimethoxy-4-methylamphetamine|DOM]] |- |[[Ergometrine]] |- |[[Ergine|LSA]] |- |[[Lysergic acid diethylamide|LSD]] |- |[[Methylphenidate]] |- |[[Mephedrone]] |- |[[Naphazoline]] |- |[[Nicotine]]<ref>{{Cite journal |last1=Hwang |first1=Kun |last2=Son |first2=Ji Soo |last3=Ryu |first3=Woo Kyung |date=November 2018 |title=Smoking and Flap Survival |journal=Plastic Surgery (Oakville, Ont.) |volume=26 |issue=4 |pages=280–285 |doi=10.1177/2292550317749509 |issn=2292-5503 |pmc=6236508 |pmid=30450347}}</ref> |- |[[Oxymetazoline]] |- |[[Phenylephrine]] |- |[[Propylhexedrine]] |- |[[Pseudoephedrine]] |- |[[Stimulant]]s |- |[[Tetrahydrozoline|Tetrahydrozoline hydrochloride]] (in eye drops) |- |[[Xylometazoline]] |}
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)